PURPOSE: Bevacizumab has demonstrated survival benefit in metastatic @entity14 (mCRC) @entity1 when combined with chemotherapy. Several randomized clinical studies have evaluated bevacizumab in combination with chemotherapy. Meta-analysis was performed to better assess the efficacy and safety of bevacizumab with chemotherapy for mCRC. MATERIALS AND METHODS: Five clinical trials randomizing a total of 3,103 mCRC @entity1 to chemotherapy alone or to the combined treatment of chemotherapy plus bevacizumab were identified. The efficacy data included progression-free survival (PFS), overall survival (OS), and overall response rate (ORR), and the safety data contained the 60-day all-cause mortality rate, adverse events (AEs), and specific @entity137 such as @entity101 , @entity715 , @entity548 , @entity644 , @entity344 , @entity294 , and @entity1210 . RESULT: There was a significant PFS benefit (P = 0.00; hazards ratio [HR] = 0.66) and OS benefit (P = 0.00; HR = 0.77) in favor of the combined treatment. The ORR was significantly higher on the bevacizumab-containing arm (P = 0.021; relative risk [RR] = 1.5), while CR was comparable between the two arms (P = 0.09). A higher incidence of grade 3/4 AEs, grade 3/4 @entity101 , grade 3/4 @entity1031 /thrombotic events, grade 3/4 @entity548 , and @entity344 was associated with the bevacizumab group. The two treatment groups were similar in terms of grade 3/4 @entity644 , grade 3/4 @entity1431 , grade 3/4 @entity294 , and the 60-day all-cause mortality rate. CONCLUSION: The addition of bevacizumab to chemotherapy confers a clinically meaningful and statistically significant improvement in OS, PFS, and ORR. Its side effects are predictable and manageable and do not compound the incidence or severity of @entity137 from chemotherapy.

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal perforation'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity1210 :: ('MESH:C536227', 'Disease') :: ['leucopenia']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
